The right answer is decrease inflammation of blocked airways (like glucocorticoids)
Inhaled glucocorticoids are the first-line anti-inflammatory agents for persistent asthma. Subject to daily administration, the resulting therapeutic benefit results in a reduction in the frequency and severity of exacerbations, a reduction in non-specific bronchial hyperreactivity and, where appropriate, an improvement in ventilatory functional parameters.
